↓ Skip to main content

Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy

Overview of attention for article published in Clinical Cancer Research, January 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
11 news outlets
twitter
3 X users

Citations

dimensions_citation
19 Dimensions

Readers on

mendeley
20 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy
Published in
Clinical Cancer Research, January 2016
DOI 10.1158/1078-0432.ccr-14-3239
Pubmed ID
Authors

Adrian M. Eiden, Shuling Zhang, Joy M. Gary, John K. Simmons, Beverly A. Mock

Abstract

As one of the earliest examples of "chemical biology," the Mechanistic Target of Rapamycin (mTOR) protein and its chemical inhibitors have been extensively studied across a spectrum of physiological and pathological processes at the molecular, organismal, and patient population levels. There are several FDA-approved mTOR inhibitors (sirolimus, everolimus and temsirolimus) with indications for cancer treatment and for prevention of solid organ rejection. Dozens of mTOR inhibitors are currently being evaluated in hundreds of on-going clinical trials across a spectrum of diseases, including numerous cancer indications, autoimmune diseases, and a number of congenital disorders. As many of the approved and investigational indications for mTOR inhibitors require long-term treatment, the magnitude and incidence of particular side effects differs from those observed in shorter-term treatments. Here, we focus on the particular increased risk of infections while receiving mTOR inhibitors. While increased infection rates might be expected from a class of drugs approved as post-transplant immunosuppressants, we review reports from clinical, mechanistic, and genetically engineered mouse model (GEMM) studies detailing a much more nuanced view of mTOR inhibitor drug action and target biology.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 5%
Unknown 19 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 20%
Other 3 15%
Student > Bachelor 2 10%
Student > Ph. D. Student 2 10%
Lecturer > Senior Lecturer 1 5%
Other 4 20%
Unknown 4 20%
Readers by discipline Count As %
Medicine and Dentistry 7 35%
Biochemistry, Genetics and Molecular Biology 2 10%
Agricultural and Biological Sciences 2 10%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Chemical Engineering 1 5%
Other 1 5%
Unknown 6 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 91. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 March 2024.
All research outputs
#467,968
of 25,504,429 outputs
Outputs from Clinical Cancer Research
#243
of 13,251 outputs
Outputs of similar age
#8,189
of 403,080 outputs
Outputs of similar age from Clinical Cancer Research
#2
of 181 outputs
Altmetric has tracked 25,504,429 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,251 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.7. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 403,080 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 181 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.